Cite
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS -mutated rectal cancer: A phase I/II trial (SAKK 41/08)
MLA
Dieter Koeberle, et al. “Neoadjuvant Radiotherapy Combined with Capecitabine and Sorafenib in Patients with Advanced KRAS -Mutated Rectal Cancer: A Phase I/II Trial (SAKK 41/08).” European Journal of Cancer, vol. 89, Jan. 2018, pp. 82–89. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....25cce4408327ec96fdd9f5dbdf09eaa1&authtype=sso&custid=ns315887.
APA
Dieter Koeberle, Ludwig Plasswilm, Roger von Moos, Piercarlo Saletti, Dirk Klingbiel, Daniela Bärtschi, Ralph Winterhalder, Martin D. Berger, Pu Yan, Arnaud Roth, György Bodoky, Panagiotis Samaras, Paola Izzo, Daniel R. Zwahlen, Daniel Rauch, Stefanie Hayoz, Urs R. Meier, Sabina Schacher, & Kathrin Zaugg. (2018). Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS -mutated rectal cancer: A phase I/II trial (SAKK 41/08). European Journal of Cancer, 89, 82–89.
Chicago
Dieter Koeberle, Ludwig Plasswilm, Roger von Moos, Piercarlo Saletti, Dirk Klingbiel, Daniela Bärtschi, Ralph Winterhalder, et al. 2018. “Neoadjuvant Radiotherapy Combined with Capecitabine and Sorafenib in Patients with Advanced KRAS -Mutated Rectal Cancer: A Phase I/II Trial (SAKK 41/08).” European Journal of Cancer 89 (January): 82–89. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....25cce4408327ec96fdd9f5dbdf09eaa1&authtype=sso&custid=ns315887.